A systematic review of the applications of the real option value of medical technologies in oncology
The ROV represents a critical dimension in evaluating medical technologies in oncology, where innovation is rapid. The implications of ROV extend beyond oncology, with the potential to influence funding, pricing, and access decisions in other disease areas as well. However, challenges such as oversimplification of assumptions for forecasting, methodological consistency, and lack of standardized framework remain pervasive. This systematic review underscores the need to integrate ROV into Health Technology Assessment practices to inform resource allocation and policy decisions.
Authors
- Fatimah Sherbeny (ORCID: https://orcid.org/0000-0003-1597-3967)
- Askal Ayalew Ali (ORCID: https://orcid.org/0000-0002-0535-6300)
- Vakaramoko Diaby (ORCID: https://orcid.org/0000-0002-6251-0773)
- Sandra Suther (ORCID: https://orcid.org/0000-0001-6440-3974)
- Meng Li (ORCID: https://orcid.org/0000-0001-6631-0819)
- K Adjei (ORCID: https://orcid.org/0009-0006-8492-7111)
Institutions
- Tufts Medical Center (US)
- Otsuka Pharmaceutical (Spain) (ES)
- Florida Agricultural and Mechanical University (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-09-26
- DOI
- https://doi.org/10.18553/jmcp.2025.31.10.1062
- Primary Topic
- Advances in Oncology and Radiotherapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00